Sanofi $SNY Shares Bought by Rockefeller Capital Management L.P.

Rockefeller Capital Management L.P. increased its stake in shares of Sanofi (NASDAQ:SNY) by 31.9% during the 4th quarter, HoldingsChannel.com reports. The fund owned 523,168 shares of the company’s stock after purchasing an additional 126,381 shares during the period. Rockefeller Capital Management L.P.’s holdings in Sanofi were worth $25,353,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Advisory Services Network LLC boosted its holdings in Sanofi by 1.4% in the third quarter. Advisory Services Network LLC now owns 15,733 shares of the company’s stock valued at $743,000 after purchasing an additional 210 shares during the last quarter. Savant Capital LLC lifted its position in shares of Sanofi by 2.7% in the 4th quarter. Savant Capital LLC now owns 8,623 shares of the company’s stock worth $418,000 after buying an additional 225 shares during the last quarter. Wesbanco Bank Inc. boosted its stake in Sanofi by 4.9% in the fourth quarter. Wesbanco Bank Inc. now owns 4,927 shares of the company’s stock valued at $239,000 after acquiring an additional 230 shares during the period. IFG Advisory LLC boosted its position in Sanofi by 2.7% during the 4th quarter. IFG Advisory LLC now owns 9,213 shares of the company’s stock valued at $446,000 after purchasing an additional 244 shares during the period. Finally, GAMMA Investing LLC boosted its holdings in shares of Sanofi by 5.5% during the fourth quarter. GAMMA Investing LLC now owns 5,058 shares of the company’s stock valued at $245,000 after acquiring an additional 264 shares during the period. 14.03% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on SNY. Argus upgraded Sanofi to a “strong-buy” rating in a research report on Monday, April 27th. Citigroup restated a “neutral” rating on shares of Sanofi in a research report on Monday, April 13th. BNP Paribas Exane lowered Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price objective for the company. in a research note on Monday, April 20th. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research report on Thursday, March 19th. Finally, Morgan Stanley set a $52.00 price target on Sanofi in a report on Friday, May 1st. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $51.00.

Sanofi Stock Performance

Shares of NASDAQ SNY opened at $41.78 on Tuesday. Sanofi has a 52 week low of $40.89 and a 52 week high of $52.68. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.22 and a current ratio of 1.01. The business’s 50-day simple moving average is $44.59 and its 200-day simple moving average is $46.22. The firm has a market cap of $101.29 billion, a price-to-earnings ratio of 11.67, a P/E/G ratio of 1.04 and a beta of 0.34.

Sanofi Increases Dividend

The company also recently announced an annual dividend, which was paid on Wednesday, June 3rd. Investors of record on Monday, May 4th were paid a $2.4225 dividend. This represents a yield of 559.0%. The ex-dividend date was Monday, May 4th. This is a boost from Sanofi’s previous annual dividend of $2.04. Sanofi’s dividend payout ratio (DPR) is 49.16%.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.